Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
661-680 of 1,694 trials

Tonsillitis Treatment: Antibiotic vs. No Treatment

We are studying whether an antibiotic can help reduce symptoms in patients with severe tonsillitis who test negative for Streptococcus group A. This trial compares the antibiotic to usual care without antibiotics.

Tonsilitis>2 yearsMonitoring phase (IV)Standard MedicinesInternal MedicineOtolaryngology

Lupus Nephritis: Ianalumab Study

We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.

Lupus Nephritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrologyRheumatology

Neuroendocrine Tumors: Personalized vs. Standard RadioTherapy

We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.

Neuroendocrine Tumors6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Kidney Health in Type 2 Diabetes: Empagliflozin and Finerenone Study

We are exploring how well two medications work for kidney health in people with type 2 diabetes. This remote trial aims to personalize treatment based on individual responses.

Type 2 DiabetesAlbuminuria≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteDiabetologyInternal MedicineNephrology

Multiple Myeloma: Treatment-Free Interval Study

We are exploring whether a treatment-free interval is safe and effective for newly diagnosed multiple myeloma patients receiving a combination of Daratumumab, Lenalidomide, and Dexamethasone. The study aims to compare the effects of continuous treatment versus a break in therapy.

Multiple Myeloma>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Hyponatremia: Empagliflozin Treatment Study

We are investigating whether empagliflozin can help increase sodium levels in patients with euvolemic or hypervolemic hyponatremia. The study will also look at its effects on related symptoms and overall health.

Low Sodium Levels (Hyponatremia)≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyInternal Medicine

Advanced Melanoma: Vusolimogene Oderparepvec with Nivolumab

We are comparing a new treatment combination for advanced melanoma that has worsened after other therapies. The goal is to see if this combination improves survival and response compared to standard treatment options.

Advanced MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesDermatologyOncology

Graft-Versus-Host Disease: Corticosteroids with ECP

We are studying whether adding extracorporeal photopheresis to corticosteroids helps patients with Grade II acute graft-versus-host disease after stem cell transplantation. This trial compares treatment outcomes and side effects between the two approaches.

Acute Graft-Versus-Host Disease (GVHD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

BRAF V600E Mutated Metastatic Colorectal Cancer: ENCORAFENIB and FOLFIRI

We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.

Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HIV Treatment Comparison: Doravirine vs. Dolutegravir

We are studying whether doravirine is as effective as dolutegravir for people newly diagnosed with HIV-1. The trial also examines potential side effects and health changes over time.

HIV Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

HIV and HBV Co-Infection: Antiviral Treatment Strategies

We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.

Co-infection with HIV-1 and HBV>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHepatologyInfectious Diseases

Cytomegalovirus in Pregnancy: Valacyclovir Study

We are comparing the effectiveness and safety of valacyclovir for treating primary cytomegalovirus infection in pregnant women. The study looks at how different doses may impact treatment outcomes and safety.

CMV Infection6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Colorectal Cancer: PD L 506 Oral Medication Study

We are investigating the safety of a new oral medication for patients with colorectal cancer and healthy volunteers. The study also looks at whether urine tests can help in diagnosing colorectal cancer.

Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Erythema Migrans: Saccharomyces boulardii Probiotic Study

We are studying the effects of a probiotic on gut health in patients taking antibiotics for erythema migrans. The goal is to see if it helps prevent diarrhea and improves gut balance during treatment.

Erythema Migrans6-12 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesGastroenterologyInfectious Diseases

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Metastatic Colorectal and Gastroesophageal Cancer: Trifluridine/Tipiracil Study

We are studying the safety of Trifluridine/tipiracil as a new chemotherapy for patients with metastatic colorectal or gastroesophageal cancer who have a specific genetic deficiency. This trial aims to see if it can be a safer alternative to traditional treatments.

Metastatic Colon or Rectal Cancer with DPD Deficiency1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Ovarian Stimulation Methods for Embryo Accumulation

We are comparing two approaches to ovarian stimulation in patients preparing for embryo testing. The goal is to see if one method produces more healthy embryos than the other.

Female InfertilityMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Erosive Esophagitis: Oral Pantoprazole for Kids and Teens

We are studying how well oral pantoprazole works for maintaining healing in children and teens aged 1 to 17 with erosive esophagitis. We also want to understand its safety and how well they tolerate the treatment.

Erosive Esophagitis6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteGastroenterologyPediatrics

Epidermolysis Bullosa Simplex: Apremilast Study

We are investigating whether apremilast can improve symptoms in patients over 6 years old with epidermolysis bullosa simplex. The study will also look at the safety of the treatment and how it affects quality of life.

Epidermolysis Bullosa Simplex3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesDermatologyRheumatology